Clinical Trial Update: Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dupilumab as add-on therapy for hypereosinophilic syndrome in patients with partial response to eosinophil-depleting biologics; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hypereosinophilic Syndrome | Phase 2 | Status: RECRUITING